Lung Cancer
Conditions
Keywords
Albumin-binding taxol
Brief summary
The investigators conduct the real world study to explore the efficacy and safety of Albumin-binding taxol in lung cancer .
Interventions
None listed
Sponsors
The First Affiliated Hospital of Anhui Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients . 2. Confirmed by Histopathology or Cytology of Lung Cancer 3. Patients should be voluntary to the trial and provide with signed informed consent 4. The researchers believe patients can benefit from the study.
Exclusion criteria
1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Albumin-binding taxol or its accessories 2. Pregnant or lactating women 3. Patients with Albumin-binding taxol contraindications 4. Patients of doctors considered unsuitable for the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progress free survival | 1 year | Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 3 year | overall survival is defined as the length of time from random assignment to death or to last contact. |
| disease control rate | 1 year | Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1 |
| Objective tumor response rate | 1 year | Objective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments |
Other
| Measure | Time frame | Description |
|---|---|---|
| Quality of life score | 1 year | Quality of life score is a questionnaire developed to assess the quality of life of cancer patients. |
| adverse events | 1 year | adverse events are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. |
Countries
China
Outcome results
None listed